Exploring functional strength changes during nusinersen treatment in symptomatic children with SMA types 2 and 3

Neuromuscul Disord. 2024 Aug:41:1-7. doi: 10.1016/j.nmd.2024.05.011. Epub 2024 May 23.

Abstract

The Hammersmith Functional Motor Scale-Expanded (HFMSE) is a validated outcome measure for monitoring changes in functional strength in patients with spinal muscular atrophy (SMA). The objective of this study was to explore changes in HFMSE item-scores in children with SMA types 2 and 3a treated with nusinersen over a period of six to twenty months. We stratified patients according to motor ability (sitting and walking), and calculated numbers and percentages for each specific improvement (positive score change) or decrease (negative score change) for the total group and each subgroup and calculated frequency distributions of specific score changes. Ninety-one percent of the children showed improvement in at least 1 item, twenty-eight percent showed a score decrease in 1 or more items. In the first six to twenty months of nusinersen treatment motor function change was characterized by the acquisition of the ability to perform specific tasks with compensation strategies (score changes from 0 to 1). Children with the ability to sit were most likely to improve in items that assess rolling, whilst children with the ability to walk most likely improved in items that assess half-kneeling. The ability most frequently lost was hip flexion in supine position.

Keywords: HFMSE; Motor function; Nusinersen; Spinal muscular atrophy; Treatment.

MeSH terms

  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Male
  • Muscle Strength / drug effects
  • Oligonucleotides* / pharmacology
  • Oligonucleotides* / therapeutic use
  • Spinal Muscular Atrophies of Childhood* / drug therapy
  • Spinal Muscular Atrophies of Childhood* / physiopathology
  • Treatment Outcome
  • Walking / physiology

Substances

  • nusinersen
  • Oligonucleotides